Sanofi to start human trials of its second coronavirus vaccine candidate
This picture taken on November 23, 2020 shows a bottle reading “Vaccine Covid-19” next to French biopharmaceutical company Sanofi logo on November 23, 2020. (Photo by JOEL SAGET / AFP)
PARIS — French pharmaceutical firm Sanofi on Friday announced the launch of human trials of its second COVID-19 vaccine, with its first still in the testing phase after having fallen behind in development.
Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology.
The phase 1 and 2 trials aim to verify that the vaccine is not dangerous and to provide initial information on its effectiveness.
Phase 3 would be carried out on many more patients to determine its effectiveness.
The first trials will include 415 people, with inital results expected in the third quarter.
Article continues after this advertisementMessenger RNA technology is also used in the Pfizer/BioNTech and Moderna vaccines, already authorized in the European Union, the United States and elsewhere.
Article continues after this advertisementIt is the second vaccine developed by Sanofi against the coronavirus.
An earlier candidate, developed with Britain’s GSK, is recombinant protein-based, but its development is several months behind schedule and testing is only in phase 2, with hopes to launch it in late 2021.
Sanofi has also agreed to help produce COVID vaccines developed by Pfizer and Johnson & Johnson.
For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this
